COST BURDEN ASSOCIATED WITH ADVANCED NON-SMALL CELL LUNG CANCER (A-NSCLC)- IMPACT OF DISEASE STAGE
Author(s)
Wood R1, Taylor-Stokes G1, Lees M2, Chirita O3
1Adelphi Real World, Macclesfield, UK, 2Bristol-Myers Squibb, Rueil Malmaison, France, 3Bristol-Myers Squibb, Uxbridge, Middlesex, UK
OBJECTIVES: To quantify the financial burden of A-NSCLC from a patient and caregiver perspective and to evaluate the impact of disease stage on costs. METHODS: Financial data were collected between May 2015 and June 2016 as part of a multinational (France, Germany and Italy), cross-sectional study of adult patients with A-NSCLC (Stage IIIB/IV) and their informal caregivers. Data were obtained via medical chart reviews and patient and caregiver self-completion forms and included, but were not limited to: wage/productivity losses, formal/informal care requirements, government financial support and out-of-pocket expenses. Statistical significance was assessed using Mann–Whitney U tests. RESULTS: In total, patients were largely receiving chemotherapy, regardless of line of therapy. Mean annual wage losses, productivity losses, unadjusted out-of-pocket costs and out-of-pocket costs adjusted for government financial support were €2076.86, €8743.73, €3774.33 and €822.66 (patients); and €436.47, €7041.79, €1755.59 and €1019.31 (caregivers). Mean annual societal costs for A-NSCLC were €12,588.64 (patients) and €7786.39 (caregivers). Mean annual wage losses, productivity losses, unadjusted out-of-pocket costs and out-of-pocket costs adjusted for government financial support were higher for Stage IV versus Stage IIIB disease for patients (€2281.84 vs €499.44, P=0.0135; €8791.00 vs €8438.62, P=NS; €4019.95 vs €1545.51, P=0.0306; €848.71 vs €583.73, P=NS) with a similar but non-significant trend for caregivers (€473.28 vs €0.00; €7180.15 vs €4482.07; €1893.61 vs €493.71; €1085.42 vs €414.40). Mean annual societal costs for A-NSCLC were higher for Stage IV disease for patients (€12,654.32 vs €11,918.75) and caregivers (€8015.91 vs €5261.57). CONCLUSIONS: A-NSCLC is associated with a substantial financial burden for patients, caregivers and society. In this analysis, mean annual societal costs for a patient with A-NSCLC and their accompanying caregiver support exceeded €20,000. Furthermore, the findings indicate that costs related to NSCLC increase as the disease progresses.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PCN87
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology